A comparison of the fragmentation thresholds and inertial cavitation doses of different ultrasound contrast agents.
Contrast bubble destruction is important in several new diagnostic and therapeutic applications. The pressure threshold of destruction is determined by the shell material, while the propensity for of the bubbles to undergo inertial cavitation (IC) depends both on the gas and shell properties of the ultrasound contrast agent (UCA). The ultrasonic fragmentation thresholds of three specific UCAs (Optison, Sonazoid, and biSpheres), each with different shell and gas properties, were determined under various acoustic conditions. The acoustic emissions generated by the agents, or their derivatives, characteristic of IC after fragmentation, was also compared, using cumulated broadband-noise emissions (IC "dose"). Albumin-shelled Optison and surfactant-shelled Sonazoid had low fragmentation thresholds (mean = 0.13 and 0.15 MPa at 1.1 MHz, 0.48 and 0.58 MPa at 3.5 MHz, respectively), while polymer-shelled biSpheres had a significant higher threshold (mean = 0.19 and 0.23 MPa at 1.1 MHz, 0.73 and 0.96 MPa for thin- and thick-shell biSpheres at 3.5 MHz, respectively, p<0.01). At comparable initial concentrations, surfactant-shelled Sonazoid produced a much larger IC dose after shell destruction than did either biSpheres or Optison (p<0.01). Thick-shelled biSpheres had the highest fragmentation threshold and produced the lowest IC dose. More than two and five acoustic cycles, respectively, were necessary for the thin- and thick-shell biSpheres to reach a steady-state fragmentation threshold.
Chen
Wen-Shiang
WS
Center for Industrial and Medical Ultrasound, Applied Physics Laboratory, University of Washington, Seattle, Washington 98105, USA. wschen@duke.edu
Matula
Thomas J
TJ
Brayman
Andrew A
AA
Crum
Lawrence A
LA
D000399:Air Pressure; D000418:Albumins / Q000493:pharmacokinetics*; D003287:Contrast Media / Q000493:pharmacokinetics*; D005290:Ferric Compounds / Q000493:pharmacokinetics*; D005466:Fluorocarbons / Q000493:pharmacokinetics*; D006801:Humans; D007501:Iron / Q000493:pharmacokinetics*; D008863:Microspheres; D010087:Oxides / Q000493:pharmacokinetics*; D010316:Particle Size; D013329:Structure-Activity Relationship; D014463:Ultrasonography
D000418:Albumins; D003287:Contrast Media; C099458:FS 069; D005290:Ferric Compounds; D005466:Fluorocarbons; D010087:Oxides; C069727:Sonazoid; D007501:Iron